Concerns Grow Over Safety of Aduhelm After Death of Patient Who Got the Drug

Health
By BY PAM BELLUCK from NYT Health https://ift.tt/30M07J8
via IFTTT your-feed-science, Drugs (Pharmaceuticals), Clinical Trials, Aduhelm (Drug), Alzheimer's Disease, Labeling and Labels (Product), Brain, Elderly, Deaths (Fatalities), Research Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many cases were asymptomatic.

Comments

Popular posts from this blog

U.S. Quietly Drafts Plan to End Program That Saved Millions From AIDS

The Jarring Contradiction at the Heart of Kennedy’s Agenda